

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	Suda Pharmaceuticals Ltd
ABN	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Paul Hopper
Date of last notice	21 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director and shareholder of Moreglade Pty Ltd <The Hopper Super Fund A/c>
Date of change	2 January 2020
No. of securities held prior to change	280,000 Ordinary Shares
Class	Unlisted Options
Number acquired	520,000 Unlisted Options (14/5/2022; 14.75 cents) 520,000 Unlisted Options (14/5/2022; 15.75 cents) 560,000 Unlisted Options (14/5/2022; 16.75 cents)
Number disposed	nil

+ See chapter 19 for defined terms.

For personal use only

Appendix 3Y
Change of Director's Interest Notice

<p>Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation</p>	<p>Non-cash, see 'nature of change' below.</p>
<p>No. of securities held after change</p>	<p>Held indirectly</p> <ul style="list-style-type: none"> i. 280,000 Ordinary Shares ii. 520,000 Unlisted Options (14/5/2022; 14.75 cents) iii. 520,000 Unlisted Options (14/5/2022; 15.75 cents) iv. 560,000 Unlisted Options (14/5/2022; 16.75 cents)
<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Issue of options pursuant to resolution of shareholders at the AGM held on 12 November 2019</p>

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
<p>No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed</p>	
Interest acquired	
Interest disposed	
<p>Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation</p>	
Interest after change	

+ See chapter 19 for defined terms.

For personal use only

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

Dated 6 January 2020



Joseph Ohayon
Company Secretary

+ See chapter 19 for defined terms.

For personal use only